Destiny Pharma Ltd

Activities: Ingredients Research & Development

Trending Articles

  1. Counteracting counterfeits in the pharmaceutical supply chain Sreedhar Patnala, General Manager at Systech, discusses the comprehensive benefits of embracing traceability
  2. Rousselot Rousselot is the global leader* of collagen-based solutions for the food, health and nutrition, biomedical and pharmaceutical sectors. Working in partnership with our global...
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Parenteral preparations: formulation challenges Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are...
  4. Naobios successfully optimises Sumagen's HIV vaccine for industrial production Naobios will now focus on developing processes for the cGMP manufacture of Sumagen's HIV-1 vaccine candidate
  5. Resolving capping issues in tablet manufacturing Natoli explores the various causes of capping and the methods to prevent it

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

Related Content

Drug Delivery

Positive update on the development of new XF‐platform drug formulations

Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections
Research & Development

Destiny Pharma secures £1.6 million grant to fight microbial resistance

The UK-China antimicrobial resistance programme has allocated grant to research its novel XF drugs
Recruitment

Nick Rodgers joins Destiny Pharma
Research & Development

Destiny Pharma announces research collaboration with Aston University

Partnership will see a dedicated team investigate potential antimicrobial candidates against biofilms
Media

Destiny Pharma establishes Scientific Advisory Board

Pharmaceutical

Destiny Pharma appoints Neil Clark new CEO

Bill Love, Destiny’s founder, to become Chief Scientific Officer
Ingredients

Destiny Pharma receives US FDA QIDP designation for novel antibacterial product

Lead drug product in development for the prevention of post-surgical Staphyloccocal infections
Subscribe now